シアトル・ジェネティクスの掲示板

ここ、日本の大手製薬会社を抗体技術で訴えてますね。PD1の時と同じく、その売上のいくらかはもらえる可能性はありますね。結構太くなりそうですね

気がついたら此処も上がって買いづらくなってしまった。
武田のブレンツキシマブ・ベドチンは此処のリンカー技術の開発品。

製薬各社がADCやってるので、リンカーとペイロード持ってるココには期待してます！

“This is one of several brentuximab vedotin regulatory milestones during 2017 towards our goal of expanding its availabilty globally to patients in need. We recently submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for brentuximab vedotin approval in cutaneous T-cell lymphoma based primarily on our phase III ALCANZA clinical trial, and we plan to submit a supplemental BLA to the FDA for brentuximab vedotin in frontline Hodgkin lymphoma based on the positive phase III ECHELON-1 clinical trial. We plan to follow up with submissions to Health Canada for indications in these settings,” Siegall added.

Brentuximab vedotin is currently not approved for use in Cutaneous T-Cell Lymphoma (CTCL) or frontline Hodgkin lymphoma.

Brentuximab vedotin is an antibody-drug conjugate or ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-positive tumor cells.

The drug is used in the treatment of lymphoma, a general term for a group of cancers that originate in the lymphatic system. There are two major categories of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is distinguished from other types of lymphoma by the presence of one characteristic type of cell, known as the Reed-Sternberg cell. The Reed-Sternberg cell expresses CD30.

Brentuximab Vedotin Approved by Health Canada for Post-ASCT Consolidation Treatment of Patients with Hodgkin Lymphoma

Health Canada, the federal department responsible for helping Canadians maintain and improve their health, has issued a non-conditional marketing authorization for use of brentuximab vedotin (Adcetris®; Seattle Genetics) as post-autologous stem cell transplant (ASCT) consolidation treatment of patients with Hodgkin lymphoma (HL) at increased risk of relapse or progression.

In 2013 Health Canada granted brentuximab vedotin approval with conditions for relapsed or refractory Hodgkin lymphoma and sALCL, and non-conditional approval for post-ASCT consolidation treatment of Hodgkin lymphoma patients at increased risk of relapse or progression.

シアトル・ジェネティクスについて話し合うスレッドです。
スレッドのテーマと無関係のコメント、もしくは他にふさわしいスレッドがあるコメントは削除されることがあります。

textreamのビジネス、株式、金融、投資、または証券に関するスレッドに参加する場合は、Yahoo! JAPAN利用規約を再読してください。

Yahoo! JAPANは情報の内容や正確さについて責任を負うことはできません。
その種の情報に基づいて行われた取引や投資決定に対しては、Yahoo! JAPANは何ら責任を負うものではありません。